medigraphic.com

2019, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (1)

Serological screening in donors in Mexico: advances and technology

Ayala-De la Cruz S, Flores-Aréchiga A, Llaca-Díaz J, Pérez-Chávez F, Salazar-Montalvo RG, Casillas-Vega N

Language: Spanish
References: 41
Page: 30-35
PDF size: 125.74 Kb.


ABSTRACT

The residual risk of transfusion-related infections has decreased dramatically in countries that have routinely implemented serological screening. Most of the donation in Mexico is from replacement practice, a risk factor for positive serology. In Mexico, the altruistic donation is only 2.7%. The heterogeneity of technical factors, regional factors and internal policies of each center influences the variability of data on the prevalence of positive screening, as well as the prevalence of confirmed cases. The main advantage of nucleic acid technology is the detection of donors in the period of serological window or occult infections, being occult hepatitis reports in Mexican donors from 1 to 3.4%. The limitation of available technology, the scope of the clinic and perspectives, invites us to improve technology and health policies in the interest of transfusion safety.


REFERENCES

  1. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA. 1943;121(17):1332-4.

  2. Ammann AJ, Cowan MJ, Wara DW, Weintrub P, Dritz S, Goldman H, et al. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet. 1983;1(8331):956-8.

  3. Curran JW, Lawrence DN, Jaffe H, Kaplan JE, Zyla LD, Chamberland M, et. al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med. 1984;310(2):69-75.

  4. Kim MJ, Park Q, Min HK, Kim HO. Residual risk of transfusiontransmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. BMC Infect Dis. 2012;12:160. DOI: 10.1186/ 1471-2334-12-160.

  5. Chiavetta JA, Escobar M, Newman A, He Y, Driezen P, Deeks S, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990- 2000. CMAJ. 2003;169(8):767-73.

  6. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev. 2005;18(1):12-29.

  7. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acidamplification testing. N Engl J Med. 2004;351(8):760-8.

  8. Heyns ADP, Benjamin RJ, Swanevelder JPR, Laycock ME, Pappalardo BL, Crookes RL, et al. Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA. 2006;295(5):519- 26. DOI: 10.1001/jama.295.5.519

  9. Rojo-Medina J. Enfermedades infecciosas transmitidas por transfusión. Panorama internacional en México. Gac Med Mex. 2014;150:78-83.

  10. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016;316(19):2025-35. DOI: 10.1001/jama.2016.9185

  11. Vázquez-Flores JA, Valiente-Banuet L, Marín y López RA, Sánchez-Guerrero SA. La seguridad de las reservas sanguíneas en la República Mexicana durante los años 1999 a 2003. Rev Investig Clin. 2006;58(2):101-8.

  12. Arreguín V, Álvarez P, Simón JI, Valderrama JA, Macías AE. VIH en donadores mexicanos de sangre y el riesgo calculado de la transfusión. Rev Investig Clin. 2008;60(4):278-83.

  13. Secretaría de Salud. NORMA Oficial Mexicana NOM-253- SSA1-2012 Para la disposición de sangre humana y sus componentes con fines terapéuticos. México: SSA; 2012. Disponible en: http://www.dof.gob.mx/normasOficiales/4917/ salud3a/salud3a.html

  14. García-Montalvo BM. Seropositividad de VIH, VHB, VHC y Treponema pallidum en donadores de sangre en el Sureste de México. Rev Investig Clin. 2006;58(6):567-72.

  15. Pita-Ramírez L, Torres-Ortiz GE. Prevalencia de anticuerpos virales y reaginas luéticas en donadores de sangre de un hospital. Rev Investig Clin. 1997;49(6):475- 80.

  16. Carreto-Vélez MA, Carrada-Bravo T, Martínez- Magdaleno A. Seroprevalencia de VHB, VHC y VIH en donadores de sangre en Irapuato, México. Salud Pública de México. 2003;45(Supl 5):S690-3.

  17. Serrano-Machuca JJ, Villareal-Ríos E, Galicia-Rodríguez L, Vargas-Daza ER, Martínez-González L, Mejía-Damián AF. Detección de anticuerpos circulantes en donantes de sangre en México. Rev Panam Salud Publica. 2009;26 (4):355-9.

  18. Contreras AM, Reta CB, Torres O, Celis A, Domínguez J. Sangre segura en ausencia de infecciones virales por VHB, VHC y VIH en periodo de ventana serológica de donadores. Salud Pública de México. 2011;53(Supl 1): S13-8.

  19. López-Balderas N, Hernández-Romano J, Cámara- Contreras M, Bravo-Sarmiento E, Hernández-Romano PA. Trends in prevalence of HIV and syphilis in a central blood bank of Veracruz, Mexico. Transfus Apher Sci. 2019;58(1):94-9.

  20. Valerio-Ureña J, Vásquez-Fernández F, Pérez-Sosa JA, Cortazar-Benítez LF, Chávez-Tapia NC, Ruvalcaba- Rojas OA, et al. Prevalencia de marcadores serológicos de VHB y VHC en donadores de sangre de la ciudad de Veracruz. Gac Med Mex. 2009;145(3):183-7.

  21. Sosa-Jurado F, Rosas-Murrieta NH, Guzman-Flores B, Perez-Zempoaltecalt C, Sanchez-Torres AP, Ramirez Rosete L, et al. Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA. Hepat Mon. 2016;16(6):e-36942. DOI: 10.5812/hepatmon.36942

  22. Sosa-Jurado F, Santos-López G, Guzmán-Flores B, Ruiz- Conde JI, Meléndez-Mena D, Vargas-Maldonado MT, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J. 2010;7:18. DOI: 10.1186/1743-422X-7-18

  23. Chiquete E, Sánchez LV, Becerra G, Quintero A, Maldonado M, Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican Transfusion Center. Ann Hepatol. 2005;4(4):275-8.

  24. Rivera-López MRF, Arenas-Esqueda A, Ambriz- Fernández R. ¿Son necesarios los estudios de sífilis en los donadores de sangre? Rev Med Inst Mex Seguro Soc. 2009;47(1):65-8.

  25. Hernández-Becerril N, Mejía AM, Ballinas-Verdugo MA, Garza-Murillo V, Manilla-Toquero E, López R, et al. Blood transfusion and iatrogenic risks in Mexico city. Anti- Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz. 2005; 100(2):111-6.

  26. Hernández-Romano P, Cámara-Contreras M, Bravo- Sarmiento E, López-Balderas N. Prevalence of Trypanosoma cruzi antibodies in blood donors from Veracruz State, Mexico. Transfusion. 2015;55(3):647-56. DOI: 10.1111/trf.12860

  27. Monteón VM, Reyes-López PA, Sosa-Palacio A, León-Tello G, Martínez-Murguía J, Sosa-Jurado F. Distribución heterogénea de la prevalencia de anticuerpos contra Trypanosoma cruzi en donadores de sangre en Puebla, México. Salud Salud Pública de México. 2005;47(2):116-25.

  28. Galavíz-Silva L, Molina-Garza DP, González-Santos MA, Mercado-Hernández R, González-Galavíz JR, Rosales- Encina JL, et al. Update on seroprevalence of anti- Trypanosoma cruzi antibodies among blood donors in northeast Mexico. Am J Trop Med Hyg. 2009;81(3):404-6.

  29. Torres-Padilla JC, López-Merino A, García-Escamilla RM, Gutiérrez-García JN. Seroprevalencia de anticuerpos anti-Brucella en disponentes de sangre con fines terapéuticos en tres bancos de sangre del Instituto Mexicano del Seguro Social. Gac Med Mex. 2004;140 4): 391-8.

  30. Alvarado-Esquivel C, Mercado-Suarez MF, Rodríguez- Briones A, Fallad-Torres L, Ayala-Ayala JO, Nevarez- Piedra LJ, et al. Seroepidemiology of infection with Toxoplasma gondii in healthy blood donors of Durango, Mexico. BMC Infect Dis. 2007;7:75. DOI: 10.1186/1471- 2334-7-75

  31. Alvarado-Esquivel C, Rascón-Careaga A, Hernández- Tinoco J, Corella-Madueño MAG, Sánchez-Anguiano LF, Aldana-Madrid ML, et al. Seroprevalence and Associated Risk Factors for Toxoplasma gondii Infection in Healthy Blood Donors: A Cross-Sectional Study in Sonora, Mexico. Biomed Res Int. 2016;2016:9597276. DOI: 10.1155/2016/9597276

  32. Bello-López JM, Castañeda-García C, Muñoz-Estrada C, Machorro-Pérez AJ. External quality control program in screening for infectious diseases at blood banks in Mexico. Transfus Apher Sci. 2018;57(1):97-101. DOI: 10.1016/j.transci.2018.01.004

  33. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev. 1995;8(1):1-21.

  34. Young H, Pryde J, Duncan L, Dave J. The Architect Syphilis assay for antibodies to Treponema pallidum: an automated screening assay with high sensitivity in primary syphilis. Sex Transm Infect. 2009;85(1):19-23. DOI: 10.1136/sti.2008.031872

  35. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50 (7):1495-504. DOI: 10.1111/j.1537-2995.2010.02622.x

  36. García-Montalvo BM, Ventura-Zapata LP. Molecular and serological characterization of occult hepatitis B infection in blood donors from Mexico. Ann Hepatol. 2011;10(2): 133-41.

  37. Martínez-Rodríguez ML, Uribe-Noguez LA, Arroyo- Anduiza CI, Mata-Marin JA, Benitez-Arvizu G, Portillo- López ML, et al. Prevalence and risk factors of Occult Hepatitis C infections in blood donors from Mexico City. PLoS One. 2018;13(10):e0205659. DOI: 10.1371/journal. pone.0205659

  38. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill. 2005;10(2):17-9.

  39. Hans R, Marwaha N. Nucleic acid testing-benefits and constraints. Asian J Transfus Sci. 2014;8(1):2-3. DOI: 10.4103/0973-6247.126679

  40. Waters L, Cameron M, Padula MP, Marks DC, Johnson L. Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions. Vox Sang. 2018;113(4):317-28. DOI: 10.1111/ vox.12640

  41. Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus. 2017;15(6):512-21. DOI: 10.2450/2017.0344-16




2020     |     www.medigraphic.com